<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Nitazoxanide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Nitazoxanide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Nitazoxanide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Nitazoxanide</b> is a broad-spectrum antiparasitic and broad-spectrum antiviral drug that is used in medicine for the treatment of various helminthic,  protozoal, and viral infections.<span class="mw-ref" id="cite_ref-Thiazolides_4-0"><a href="#cite_note-Thiazolides-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Nitazoxanide:_Broad-spectrum_antiparasitic_5-0"><a href="#cite_note-Nitazoxanide:_Broad-spectrum_antiparasitic-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Broad-spectrum_antiviral_review_6-0"><a href="#cite_note-Broad-spectrum_antiviral_review-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is indicated for the treatment of infection by <i>Cryptosporidium parvum</i> and <i>Giardia lamblia</i> in immunocompetent individuals and has been repurposed for the treatment of influenza.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-5"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Broad-spectrum_antiviral_review_6-1"><a href="#cite_note-Broad-spectrum_antiviral_review-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Nitazoxanide has also been shown to have <i>in vitro</i> antiparasitic activity and clinical treatment efficacy for infections caused by other protozoa and helminths;<span class="mw-ref" id="cite_ref-Thiazolides_4-1"><a href="#cite_note-Thiazolides-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-NTZ_2007_review_7-0"><a href="#cite_note-NTZ_2007_review-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> emerging evidence suggests that it possesses efficacy in treating a number of viral infections as well.<span class="mw-ref" id="cite_ref-Broad-spectrum_antiviral_review_6-2"><a href="#cite_note-Broad-spectrum_antiviral_review-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Nitazoxanide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Nitazoxanide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Nitazoxanide.svg.png" data-file-width="512" data-file-height="289" data-file-type="drawing" height="124" width="220"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Nitazoxanide-from-xtal-Mercury-3D-balls.png" tppabs="https://ptable.com/wiki/compounds/I/m/Nitazoxanide-from-xtal-Mercury-3D-balls.png" data-file-width="2000" data-file-height="1356" data-file-type="bitmap" height="149" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Alinia, Nizonide, <a href="#Brand_names">and others</a></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/nitazoxanide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/nitazoxanide.html'" tppabs="https://www.drugs.com/monograph/nitazoxanide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a603017.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a603017.html'" tppabs="https://medlineplus.gov/druginfo/meds/a603017.html" class="external text external">a603017</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Nitazoxanide&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Nitazoxanide&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Nitazoxanide&SearchType=BasicSearch" class="external text external">Nitazoxanide</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>B (No risk in non-human studies)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Oral</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Antiprotozoal<br>Broad-spectrum antiparasitic<br>Broad-spectrum antiviral</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>P01AX11<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=P01AX11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=P01AX11'" tppabs="https://www.whocc.no/atc_ddd_index/?code=P01AX11" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>Nitazoxanide:<span>&nbsp;</span>?<br>Tizoxanide: over 99%<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-0"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Primary:_Kinetics_and_OD_2-0"><a href="#cite_note-Primary:_Kinetics_and_OD-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Rapidly hydrolyzed to tizoxanide<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-1"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolites</th><td>tizoxanide<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-2"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Primary:_Kinetics_and_OD_2-1"><a href="#cite_note-Primary:_Kinetics_and_OD-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><br><span class="new">tizoxanide glucuronide</span><span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-3"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Primary:_Kinetics_and_OD_2-2"><a href="#cite_note-Primary:_Kinetics_and_OD-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>3.5<span>&nbsp;</span>hours<span class="mw-ref" id="cite_ref-PubChem_3-0"><a href="#cite_note-PubChem-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Renal, biliary, and fecal<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-4"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">[2-[(5-Nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=55981-09-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=55981-09-4'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=55981-09-4" class="external text external">55981-09-4</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/41684  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/41684'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/41684" class="external text external">41684</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00507  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00507'" tppabs="https://www.drugbank.ca/drugs/DB00507" class="external text external">DB00507</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.38037.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.38037.html'" tppabs="http://www.chemspider.com/Chemical-Structure.38037.html" class="external text external">38037</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=SOA12P041N  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=SOA12P041N'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=SOA12P041N" class="external text external">SOA12P041N</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D02486  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D02486'" tppabs="https://www.kegg.jp/entry/D02486" class="external text external">D02486</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1401  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1401'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1401" class="external text external">ChEMBL1401</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">NIAID ChemDB</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=057131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=057131'" tppabs="https://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=057131" class="external text external">057131</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID5033757  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID5033757'" tppabs="https://comptox.epa.gov/dashboard/DTXSID5033757" class="external text external">DTXSID5033757</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.054.465  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.054.465'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.054.465" class="external text external">100.054.465</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>12</sub><span>H</span><sub>9</sub><span>N</span><sub>3</sub><span>O</span><sub>5</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">307.28</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28Nc1ncc%28s1%29%5BN%2B%5D%28%5BO-%5D%29%3DO%29c2ccccc2OC%28%3DO%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28Nc1ncc%28s1%29%5BN%2B%5D%28%5BO-%5D%29%3DO%29c2ccccc2OC%28%3DO%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28Nc1ncc%28s1%29%5BN%2B%5D%28%5BO-%5D%29%3DO%29c2ccccc2OC%28%3DO%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C(Nc1ncc(s1)[N+]([O-])=O)c2ccccc2OC(=O)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:YQNQNVDNTFHQSW-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=698544483&page2=Nitazoxanide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=698544483&page2=Nitazoxanide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=698544483&page2=Nitazoxanide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Chemically, nitazoxanide is the prototype member of the <span class="new">thiazolides</span>, a class of drugs which are synthetic nitrothiazolyl-<a href="Salicylamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylamide" title="Salicylamide">salicylamide</a> derivatives with antiparasitic and antiviral activity.<span class="mw-ref" id="cite_ref-Thiazolides_4-2"><a href="#cite_note-Thiazolides-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Broad-spectrum_antiviral_review_6-3"><a href="#cite_note-Broad-spectrum_antiviral_review-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Nitrothiazolyl-salicylamide_8-0"><a href="#cite_note-Nitrothiazolyl-salicylamide-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> Tizoxanide, an active metabolite of nitazoxanide in humans, is also an antiparasitic drug of the thiazolide class.<span class="mw-ref" id="cite_ref-Thiazolides_4-3"><a href="#cite_note-Thiazolides-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-pmid17888524_9-0"><a href="#cite_note-pmid17888524-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Uses">Uses</h2></summary>
    
<p>Nitazoxanide is an effective first-line treatment for infection by <i>Blastocystis</i> species<span class="mw-ref" id="cite_ref-CDC_blastocystosis_10-0"><a href="#cite_note-CDC_blastocystosis-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Efficacy_against_Blastocystis_11-0"><a href="#cite_note-Efficacy_against_Blastocystis-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> and is indicated for the treatment of infection by <i>Cryptosporidium parvum</i> or <i>Giardia lamblia</i> in immunocompetent adults and children.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-6"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is also an effective treatment option for infections caused by other protozoa and helminths (e.g., <i>Entamoeba histolytica</i>,<span class="mw-ref" id="cite_ref-Entamoeba_12-0"><a href="#cite_note-Entamoeba-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> <i>Hymenolepis nana</i>,<span class="mw-ref" id="cite_ref-CDC_Hymenolepiasis_13-0"><a href="#cite_note-CDC_Hymenolepiasis-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> <i>Ascaris lumbricoides</i>,<span class="mw-ref" id="cite_ref-A._lumbricoides_14-0"><a href="#cite_note-A._lumbricoides-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> and <i>Cyclospora cayetanensis</i><span class="mw-ref" id="cite_ref-C._cayetanensis_15-0"><a href="#cite_note-C._cayetanensis-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span>).<span class="mw-ref" id="cite_ref-NTZ_2007_review_7-1"><a href="#cite_note-NTZ_2007_review-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p><span>As of September 2015</span>, it is in phase 3 clinical trials for the treatment influenza due to its inhibitory effect on a broad range of influenza virus subtypes and efficacy against influenza viruses that are resistant to neuraminidase inhibitors like <a href="Oseltamivir.htm" tppabs="https://ptable.com/wiki/compounds/A/Oseltamivir" title="Oseltamivir">oseltamivir</a>.<span class="mw-ref" id="cite_ref-Broad-spectrum_antiviral_review_6-4"><a href="#cite_note-Broad-spectrum_antiviral_review-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Influenza_phase_3_trial_16-0"><a href="#cite_note-Influenza_phase_3_trial-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span>  Nitazoxanide is also being researched as a potential treatment for chronic hepatitis B, chronic hepatitis C, rotavirus and norovirus gastroenteritis.<span class="mw-ref" id="cite_ref-Broad-spectrum_antiviral_review_6-5"><a href="#cite_note-Broad-spectrum_antiviral_review-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Chronic_hepatitis_B">Chronic hepatitis B</h3></summary>
    
<p>Nitazoxanide alone has shown preliminary evidence of efficacy in the treatment of chronic hepatitis B over a one-year course of therapy.<span class="mw-ref" id="cite_ref-Infectious_Diseases_2009_17-0"><a href="#cite_note-Infectious_Diseases_2009-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> Nitazoxanide 500<span>&nbsp;</span>mg twice daily resulted in a decrease in serum HBV DNA in all of 4 HBeAg-positive patients, with undetectable HBV DNA in 2 of 4 patients, loss of HBeAg in 3 patients, and loss of HBsAg in one patient. Seven of 8 HBeAg-negative patients treated with nitazoxanide 500<span>&nbsp;</span>mg twice daily had undetectable HBV DNA and 2 had loss of HBsAg. Additionally, nitazoxanide monotherapy in one case and nitazoxanide plus adefovir in another case resulted in undetectable HBV DNA, loss of HBeAg and loss of HBsAg.<span class="mw-ref" id="cite_ref-Infectious_Diseases_2008_18-0"><a href="#cite_note-Infectious_Diseases_2008-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> These preliminary studies showed a higher rate of HBsAg loss than any currently licensed therapy for chronic hepatitis B.  The similar mechanism of action of interferon and nitazoxanide suggest that stand-alone nitazoxanide therapy or nitazoxanide in concert with nucleos(t)ide analogs have the potential to increase loss of HBsAg, which is the ultimate end-point of therapy. A formal phase Ⅱ study is being planned for 2009.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Chronic_hepatitis_C">Chronic hepatitis C</h3></summary>
    
<p>Romark initially decided to focus on the possibility of treating chronic hepatitis C with nitazoxanide.<span class="mw-ref" id="cite_ref-Hepatitis_B_and_C_20-0"><a href="#cite_note-Hepatitis_B_and_C-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> The drug garnered interest from the hepatology community after three phase II clinical trials involving the treatment of hepatitis C with nitazoxanide produced positive results for treatment efficacy and similar tolerability to placebo without any signs of toxicity.<span class="mw-ref" id="cite_ref-Hepatitis_B_and_C_20-1"><a href="#cite_note-Hepatitis_B_and_C-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> A meta-analysis from 2014 concluded that the previous held trials were of low-quality and with held with a risk of bias. The authors concluded that more randomized trials with low risk of bias are needed to determine if Nitazoxanide can be used as an effective treatment for chronic hepatitis C patients.<span class="mw-ref" id="cite_ref-NikolovaGluud2014_21-0"><a href="#cite_note-NikolovaGluud2014-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Clinical_trials">Clinical trials</h3></summary>
    

<p>Romark Laboratories has announced encouraging results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus infection. The company used 675<span>&nbsp;</span>mg and 1,350<span>&nbsp;</span>mg twice daily doses of controlled release nitazoxanide showed favorable safety and tolerability throughout the course of the study, with mild to moderate adverse events. Primarily GI-related adverse events were reported.</p>

<p>Nitazoxanide has gone through Phase II clinical trials for the treatment of hepatitis C, in combination with peginterferon alfa-2a and <a href="Ribavirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ribavirin" title="Ribavirin">ribavirin</a>.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p>

<p>A randomised double-blind placebo-controlled study published in 2006, with a group of 38 young children (Lancet, vol 368, page 124-129)<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> concluded that a 3-day course of nitazoxanide significantly reduced the duration of rotavirus disease in hospitalized pediatric patients. Dose given was "7.5 mg/kg twice daily" and the time of resolution was "31 hours for those given nitazoxanide compared with 75 hours for those in the placebo group."  Rotavirus is the most common infectious agent associated with diarrhea in the pediatric age group worldwide.</p>

<p>Teran et al.. conducted a study at the Pediatric Center Albina Patinö, a reference hospital in the city of Cochabamba, Bolivia, from August 2007 to February 2008. The study compared nitazoxanide and probiotics in the treatment of acute rotavirus diarrhea. They found small differences in favor of nitazoxanide in comparison with probiotics and concluded that nitazoxanide is an important treatment option for rotavirus diarrhea.<span class="mw-ref" id="cite_ref-Infectious_Diseases_2009_17-1"><a href="#cite_note-Infectious_Diseases_2009-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Lateef <i>et al.</i>. conducted a study in India that evaluated the effectiveness of nitazoxanide in the treatment of beef tapeworm (<i>Taenia saginata</i>) infection.    They concluded that nitazoxanide is a safe, effective, inexpensive, and well-tolerated drug for the treatment of niclosamide- and praziquantel-resistant beef tapeworm (<i>Taenia saginata</i>) infection.<span class="mw-ref" id="cite_ref-Infectious_Diseases_2008_18-1"><a href="#cite_note-Infectious_Diseases_2008-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>A retrospective review of charts of patients treated with nitazoxanide for trichomoniasis by Michael Dan and Jack D. Sobel demonstrated a negative result. They reported three case studies; two of which with metronidazole-resistant infections. In Case 3, they reported the patient to be cured with high divided dose tinidazole therapy. They used a higher dosage of the drug (total dose, 14–56 g) than the recommended standard dosage (total dose, 3 g) and observed a significant adverse reaction (poorly tolerated nausea) only with the very high dose (total dose, 56 g). While confirming the safety of the drug, they showed nitazoxanide is ineffective for the treatment of trichomoniasis.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Nitazoxanide is contraindicated only in individuals who have experienced a hypersensitivity reaction to nitazoxanide or the inactive ingredients of a nitazoxanide formulation.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-7"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The side effects of nitazoxanide do not significantly differ from a placebo treatment for giardiasis;<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-8"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> these symptoms include stomach pain, headache, upset stomach, vomiting, discolored urine, excessive urinating, skin rash, itching, fever, flu syndrome, and others.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-9"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Nitazoxanide does not appear to cause any significant adverse effects when taken by healthy adults.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-10"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Primary:_Kinetics_and_OD_2-3"><a href="#cite_note-Primary:_Kinetics_and_OD-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>Information on nitazoxanide overdose is limited. Oral doses of 4<span>&nbsp;</span>grams in healthy adults do not appear to cause any significant adverse effects.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-11"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Primary:_Kinetics_and_OD_2-4"><a href="#cite_note-Primary:_Kinetics_and_OD-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span>  In various animals, the oral LD<sub>50</sub> is higher than 10<span>&nbsp;</span><abbr>g/kg</abbr>.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-12"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Due to the exceptionally high plasma protein binding (&gt;99.9%) of nitazoxanide's metabolite, tizoxanide, the concurrent use of nitazoxanide with other highly plasma protein-bound drugs with narrow therapeutic indices (e.g., <a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">warfarin</a>) increases the risk of drug toxicity.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-13"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span>  <i>In vitro</i> evidence suggests that nitazoxanide does not affect the CYP450 system.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-14"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    

<p>The anti-protozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-15"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Nitrothiazolyl-salicylamide_8-1"><a href="#cite_note-Nitrothiazolyl-salicylamide-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> PFOR inhibition may also contribute to its activity against anaerobic bacteria.<span class="mw-ref" id="cite_ref-pmid28748751_27-0"><a href="#cite_note-pmid28748751-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>

<p>It has also been shown to have activity against influenza A virus <i>in vitro</i>.<span class="mw-ref" id="cite_ref-Rossignol2009_28-0"><a href="#cite_note-Rossignol2009-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> The mechanism appears to be by selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to endoglycosidase H digestion. This impairs hemagglutinin intracellular trafficking and insertion of the protein into the host plasma membrane.</p>

<p>Nitazoxanide modulates a variety of other pathways <i>in vitro</i>, including glutathione-S-transferase and glutamate-gated chloride ion channels in nematodes, respiration and other pathways in bacteria and cancer cells, and viral and host transcriptional factors.<span class="mw-ref" id="cite_ref-pmid28748751_27-1"><a href="#cite_note-pmid28748751-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>



</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>Following oral administration, nitazoxanide is rapidly hydrolyzed to the pharmacologically active metabolite, tizoxanide, which is 99% protein bound.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-16"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-pmid17888524_9-1"><a href="#cite_note-pmid17888524-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Tizoxanide is then glucuronide conjugated into the active metabolite, <span class="new">tizoxanide glucuronide</span>.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-17"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span>  Peak plasma concentrations of the metabolites tizoxanide and tizoxanide glucuronide are observed 1–4<span>&nbsp;</span>hours after oral administration of nitazoxanide, whereas nitazoxanide itself is not detected in blood plasma.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-18"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<p>Roughly <span>​</span><span class="frac nowrap"><sup>2</sup><span>⁄</span><sub>3</sub></span> of an oral dose of nitazoxanide is excreted as its metabolites in feces, while the remainder of the dose excreted in urine.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-19"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Tizoxanide is excreted in the urine, bile and feces.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-20"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Tizoxanide glucuronide is excreted in urine and bile.<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-21"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    

<p>Nitazoxanide is the prototype member of the <span class="new">thiazolides</span>, which is a drug class of structurally-related broad-spectrum antiparasitic compounds.<span class="mw-ref" id="cite_ref-Thiazolides_4-4"><a href="#cite_note-Thiazolides-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Nitazoxanide is a light yellow crystalline powder. It is poorly soluble in ethanol and practically insoluble in water.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Nitazoxanide was originally discovered in the 1980s by Jean-François Rossignol at the Pasteur Institute. Initial studies demonstrated activity versus tapeworms. <i>In vitro</i> studies demonstrated much broader activity. Dr. Rossignol co-founded Romark Laboratories, with the goal of bringing nitazoxanide to market as an anti-parasitic drug. Initial studies in the USA were conducted in collaboration with Unimed Pharmaceuticals, Inc. (Marietta, GA) and focused on development of the drug for treatment of cryptosporidiosis in AIDS. Controlled trials began shortly after the advent of effective anti-retroviral therapies. The trials were abandoned due to poor enrollment and the FDA rejected an application based on uncontrolled studies.</p>

<p>Subsequently, Romark launched a series of controlled trials. A placebo-controlled study of nitazoxanide in cryptosporidiosis demonstrated significant clinical improvement in adults and children with mild illness. Among malnourished children in Zambia with chronic cryptosporidiosis, a three-day course of therapy led to clinical and parasitologic improvement and improved survival. In Zambia and in a study conducted in Mexico, nitazoxanide was not successful in the treatment of cryptosporidiosis in advanced infection with human immunodeficiency virus at the doses used. However, it was effective in patients with higher CD4 counts. In treatment of giardiasis, nitazoxanide was superior to placebo and comparable to <a href="Metronidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metronidazole" title="Metronidazole">metronidazole</a>. Nitazoxanide was successful in the treatment of metronidazole-resistant giardiasis. Studies have suggested efficacy in the treatment of cyclosporiasis, isosporiasis, and amebiasis.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> Recent studies have also found it to be effective against beef tapeworm(Taenia saginata).<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>

<p>Nitazoxanide is also under investigation for the treatment of COVID-19.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>Nitazoxanide showed moderate to high inhibitory efficacy against COVID-19 PL protease as demonstrated by in silico study.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmaceutical_products">Pharmaceutical products</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Dosage_forms">Dosage forms</h3></summary>
    
<p>Nitazoxanide is currently available in two oral dosage forms: a tablet (500<span>&nbsp;</span>mg) and an oral suspension (100<span>&nbsp;</span>mg per 5<span>&nbsp;</span>ml when reconstituted).<span class="mw-ref" id="cite_ref-FDA_Nitazoxanide_1-22"><a href="#cite_note-FDA_Nitazoxanide-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<p>An extended release tablet (675<span>&nbsp;</span>mg) has been used in clinical trials for chronic hepatitis C; however, this form is not currently marketed and available for prescription.<span class="mw-ref" id="cite_ref-Hepatitis_B_and_C_20-2"><a href="#cite_note-Hepatitis_B_and_C-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>Nitazoxanide is sold under the brand names Adonid, Alinia, Allpar, Annita, Celectan, Colufase, Daxon, Dexidex, Diatazox, Kidonax, Mitafar, Nanazoxid, Parazoxanide, Netazox, Niazid, Nitamax, Nitax, Nitaxide, Nitaz, Nizonide, <span class="nowrap">NT-TOX</span>, Pacovanton, Paramix, Toza, and Zox.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-FDA_Nitazoxanide-1"> <span id="mw-reference-text-cite_note-FDA_Nitazoxanide-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20160116192246/http://alinia.com/images/Alinia-Prescribing-Information.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160116192246/http://alinia.com/images/Alinia-Prescribing-Information.pdf'" tppabs="https://web.archive.org/web/20160116192246/http://alinia.com/images/Alinia-Prescribing-Information.pdf" class="external text external">"Nitazoxanide Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. Romark Pharmaceuticals. August 2013. pp.<span>&nbsp;</span>1–5. Archived from <a href="javascript:if(confirm('http://www.alinia.com/images/Alinia-Prescribing-Information.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.alinia.com/images/Alinia-Prescribing-Information.pdf'" tppabs="http://www.alinia.com/images/Alinia-Prescribing-Information.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 16 January 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">3 January</span> 2016</span>.</cite></span></li><li id="cite_note-Primary:_Kinetics_and_OD-2"> <span id="mw-reference-text-cite_note-Primary:_Kinetics_and_OD-2" class="mw-reference-text"><cite id="CITEREFStockisAllemonDe_BruynGengler2002" class="citation journal cs1">Stockis A, Allemon AM, De Bruyn S, Gengler C (May 2002). "Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses". <i>Int J Clin Pharmacol Ther</i>. <b>40</b> (5): 213–220. doi:<a href="javascript:if(confirm('https://doi.org/10.5414%2Fcpp40213  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.5414%2Fcpp40213'" tppabs="https://doi.org/10.5414%2Fcpp40213" class="external text external">10.5414/cpp40213</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12051573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12051573'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12051573" class="external text external">12051573</a>.</cite></span></li><li id="cite_note-PubChem-3"> <span id="mw-reference-text-cite_note-PubChem-3" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/nitazoxanide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/nitazoxanide'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/nitazoxanide" class="external text external">"Nitazoxanide"</a>. <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">3 January</span> 2016</span>.</cite></span></li><li id="cite_note-Thiazolides-4"> <span id="mw-reference-text-cite_note-Thiazolides-4" class="mw-reference-text"><cite id="CITEREFDi_SantoEhrisman2013" class="citation journal cs1">Di Santo N, Ehrisman J (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795384'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795384" class="external text external">"Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?"</a>. <i>Cancers (Basel)</i>. <b>5</b> (3): 1163–1176. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fcancers5031163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fcancers5031163'" tppabs="https://doi.org/10.3390%2Fcancers5031163" class="external text external">10.3390/cancers5031163</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795384'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795384" class="external text external">3795384</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24202339  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24202339'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24202339" class="external text external">24202339</a>. <q>Nitazoxanide [NTZ: 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide] is a thiazolide antiparasitic agent with excellent activity against a wide variety of protozoa and helminths. <span>&nbsp;</span>... Nitazoxanide (NTZ) is a main compound of a class of broad-spectrum anti-parasitic compounds named thiazolides. It is composed of a nitrothiazole-ring and a salicylic acid moiety which are linked together by an amide bond<span>&nbsp;</span>... NTZ is generally well tolerated, and no significant adverse events have been noted in human trials [13].<span>&nbsp;</span>... In vitro, NTZ and tizoxanide function against a wide range of organisms, including the protozoal species Blastocystis hominis, C. parvum, Entamoeba histolytica, G. lamblia and Trichomonas vaginalis [13]</q></cite></span></li><li id="cite_note-Nitazoxanide:_Broad-spectrum_antiparasitic-5"> <span id="mw-reference-text-cite_note-Nitazoxanide:_Broad-spectrum_antiparasitic-5" class="mw-reference-text"><cite id="CITEREFWhite2004" class="citation journal cs1">White CA (2004). "Nitazoxanide: a new broad spectrum antiparasitic agent". <i>Expert Rev Anti Infect Ther</i>. <b>2</b> (1): 43–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2F14787210.2.1.43  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2F14787210.2.1.43'" tppabs="https://doi.org/10.1586%2F14787210.2.1.43" class="external text external">10.1586/14787210.2.1.43</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15482170  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15482170'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15482170" class="external text external">15482170</a>.</cite></span></li><li id="cite_note-Broad-spectrum_antiviral_review-6"> <span id="mw-reference-text-cite_note-Broad-spectrum_antiviral_review-6" class="mw-reference-text"><cite id="CITEREFRossignol2014" class="citation journal cs1">Rossignol JF (October 2014). <a href="javascript:if(confirm('https://doi.org/10.1016/j.antiviral.2014.07.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.antiviral.2014.07.014'" tppabs="https://doi.org/10.1016/j.antiviral.2014.07.014" class="external text external">"Nitazoxanide: a first-in-class broad-spectrum antiviral agent"</a>. <i>Antiviral Res</i>. <b>110</b>: 94–103. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.antiviral.2014.07.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.antiviral.2014.07.014'" tppabs="https://doi.org/10.1016%2Fj.antiviral.2014.07.014" class="external text external">10.1016/j.antiviral.2014.07.014</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25108173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25108173'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25108173" class="external text external">25108173</a>. <q>Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza.<span>&nbsp;</span>... From a chemical perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides. These small-molecule drugs target host-regulated processes involved in viral replication.<span>&nbsp;</span>... A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clinical development for the treatment of influenza. Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors.<span>&nbsp;</span>... Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, coronavirus, rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays. Clinical trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C. Ongoing and future clinical development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever.</q></cite></span></li><li id="cite_note-NTZ_2007_review-7"> <span id="mw-reference-text-cite_note-NTZ_2007_review-7" class="mw-reference-text"><cite id="CITEREFAndersonCurran2007" class="citation journal cs1">Anderson, V. R.; Curran, M. P. (2007). "Nitazoxanide: A review of its use in the treatment of gastrointestinal infections". <i>Drugs</i>. <b>67</b> (13): 1947–1967. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200767130-00015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200767130-00015'" tppabs="https://doi.org/10.2165%2F00003495-200767130-00015" class="external text external">10.2165/00003495-200767130-00015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17722965  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17722965'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17722965" class="external text external">17722965</a>. <q>Nitazoxanide is effective in the treatment of protozoal and helminthic infections<span>&nbsp;</span>... Nitazoxanide is a first-line choice for the treatment of illness caused by C. parvum or G. lamblia infection in immunocompetent adults and children, and is an option to be considered in the treatment of illnesses caused by other protozoa and/or helminths.</q></cite></span></li><li id="cite_note-Nitrothiazolyl-salicylamide-8"> <span id="mw-reference-text-cite_note-Nitrothiazolyl-salicylamide-8" class="mw-reference-text"><cite class="citation journal cs1">Sisson G1, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, Hoffman PS. (July 2002). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127316  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127316'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127316" class="external text external">"Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori"</a>. <i>Antimicrob. Agents Chemother</i>. <b>46</b> (7): 2116–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1128%2Faac.46.7.2116-2123.2002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1128%2Faac.46.7.2116-2123.2002'" tppabs="https://doi.org/10.1128%2Faac.46.7.2116-2123.2002" class="external text external">10.1128/aac.46.7.2116-2123.2002</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127316  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127316'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127316" class="external text external">127316</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12069963  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12069963'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12069963" class="external text external">12069963</a>. <q>Nitazoxanide (NTZ) is a redox-active nitrothiazolyl-salicylamide</q></cite><span class="cs1-maint citation-comment">CS1 maint: uses authors parameter (link)</span></span></li><li id="cite_note-pmid17888524-9"> <span id="mw-reference-text-cite_note-pmid17888524-9" class="mw-reference-text"><cite id="CITEREFKorba_BEMontero_ABFarrar_KGaye2008" class="citation journal cs1">Korba BE, Montero AB, Farrar K,  et al. (January 2008). "Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication". <i>Antiviral Res</i>. <b>77</b> (1): 56–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.antiviral.2007.08.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.antiviral.2007.08.005'" tppabs="https://doi.org/10.1016%2Fj.antiviral.2007.08.005" class="external text external">10.1016/j.antiviral.2007.08.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17888524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17888524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17888524" class="external text external">17888524</a>.</cite></span></li><li id="cite_note-CDC_blastocystosis-10"> <span id="mw-reference-text-cite_note-CDC_blastocystosis-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cdc.gov/parasites/blastocystis/health_professionals/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cdc.gov/parasites/blastocystis/health_professionals/'" tppabs="https://www.cdc.gov/parasites/blastocystis/health_professionals/" class="external text external">"Blastocystis: Resources for Health Professionals"</a>. United States Centers for Disease Control and Prevention. 2017-05-02<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2016</span>.</cite></span></li><li id="cite_note-Efficacy_against_Blastocystis-11"> <span id="mw-reference-text-cite_note-Efficacy_against_Blastocystis-11" class="mw-reference-text"><cite id="CITEREFRobertsStarkHarknessEllis2014" class="citation journal cs1">Roberts T, Stark D, Harkness J, Ellis J (May 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988" class="external text external">"Update on the pathogenic potential and treatment options for Blastocystis sp"</a>. <i>Gut Pathog</i>. <b>6</b>: 17. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1757-4749-6-17  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1757-4749-6-17'" tppabs="https://doi.org/10.1186%2F1757-4749-6-17" class="external text external">10.1186/1757-4749-6-17</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988" class="external text external">4039988</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24883113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24883113'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24883113" class="external text external">24883113</a>. <q>Blastocystis is one of the most common intestinal protists of humans.<span>&nbsp;</span>... A recent study showed that 100% of people from low socio-economic villages in Senegal were infected with Blastocystis sp. suggesting that transmission was increased due to poor hygiene sanitation, close contact with domestic animals and livestock, and water supply directly from well and river [10].<span>&nbsp;</span>...<br><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988/table/T2/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988/table/T2/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039988/table/T2/" class="external text external">Table 2: Summary of treatments and efficacy for Blastocystis infection</a></q></cite></span></li><li id="cite_note-Entamoeba-12"> <span id="mw-reference-text-cite_note-Entamoeba-12" class="mw-reference-text"><cite id="CITEREFMuñozValerioEworoBouza2011" class="citation journal cs1">Muñoz P, Valerio M, Eworo A, Bouza E (2011). <a href="javascript:if(confirm('http://onlinelibrary.wiley.com/doi/10.1111/ajt.12120/pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://onlinelibrary.wiley.com/doi/10.1111/ajt.12120/pdf'" tppabs="http://onlinelibrary.wiley.com/doi/10.1111/ajt.12120/pdf" class="external text external">"Parasitic infections in solid-organ transplant recipients"</a>. <i>Curr Opin Organ Transplant</i>. <b>16</b> (6): 565–575. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FMOT.0b013e32834cdbb0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FMOT.0b013e32834cdbb0'" tppabs="https://doi.org/10.1097%2FMOT.0b013e32834cdbb0" class="external text external">10.1097/MOT.0b013e32834cdbb0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22027588  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22027588'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22027588" class="external text external">22027588</a><span class="reference-accessdate">. Retrieved <span class="nowrap">7 January</span> 2016</span>. <q>Nitazoxanide: intestinal amoebiasis: 500 mg po bid x 3 days</q></cite></span></li><li id="cite_note-CDC_Hymenolepiasis-13"> <span id="mw-reference-text-cite_note-CDC_Hymenolepiasis-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cdc.gov/parasites/hymenolepis/health_professionals/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cdc.gov/parasites/hymenolepis/health_professionals/'" tppabs="https://www.cdc.gov/parasites/hymenolepis/health_professionals/" class="external text external">"Hymenolepiasis: Resources for Health Professionals"</a>. United States Centers for Disease Control and Prevention. 2017-05-02<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2016</span>.</cite></span></li><li id="cite_note-A._lumbricoides-14"> <span id="mw-reference-text-cite_note-A._lumbricoides-14" class="mw-reference-text"><cite id="CITEREFHagelGiusti2010" class="citation journal cs1">Hagel I, Giusti T (October 2010). <a href="javascript:if(confirm('https://semanticscholar.org/paper/c81963c850e97926f7b12fab8b76af2dddc6f9d4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/c81963c850e97926f7b12fab8b76af2dddc6f9d4'" tppabs="https://semanticscholar.org/paper/c81963c850e97926f7b12fab8b76af2dddc6f9d4" class="external text external">"Ascaris lumbricoides: an overview of therapeutic targets"</a>. <i>Infectious Disorders - Drug Targets</i>. <b>10</b> (5): 349–67. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F187152610793180876  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F187152610793180876'" tppabs="https://doi.org/10.2174%2F187152610793180876" class="external text external">10.2174/187152610793180876</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20701574  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20701574'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20701574" class="external text external">20701574</a>. <q>new anthelmintic alternatives such as tribendimidine and Nitazoxanide have proved to be safe and effective against A. lumbricoides and other soil-transmitted helminthiases in human trials.</q></cite></span></li><li id="cite_note-C._cayetanensis-15"> <span id="mw-reference-text-cite_note-C._cayetanensis-15" class="mw-reference-text"><cite id="CITEREFShoff_WH2015" class="citation web cs1">Shoff WH (5 October 2015).  Chandrasekar PH, Talavera F, King JW (eds.). <a href="javascript:if(confirm('http://emedicine.medscape.com/article/236105-medication  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://emedicine.medscape.com/article/236105-medication'" tppabs="http://emedicine.medscape.com/article/236105-medication" class="external text external">"Cyclospora Medication"</a>. <i>Medscape</i>. WebMD<span class="reference-accessdate">. Retrieved <span class="nowrap">11 January</span> 2016</span>. <q>Nitazoxanide, a 5-nitrothiazole derivative with broad-spectrum activity against helminths and protozoans, has been shown to be effective against C cayetanensis, with an efficacy 87% by the third dose (first, 71%; second 75%). Three percent of patients had minor side effects.</q></cite></span></li><li id="cite_note-Influenza_phase_3_trial-16"> <span id="mw-reference-text-cite_note-Influenza_phase_3_trial-16" class="mw-reference-text"><cite id="CITEREFLiChanLee2015" class="citation journal cs1">Li TC, Chan MC, Lee N (September 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294" class="external text external">"Clinical Implications of Antiviral Resistance in Influenza"</a>. <i>Viruses</i>. <b>7</b> (9): 4929–4944. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fv7092850  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fv7092850'" tppabs="https://doi.org/10.3390%2Fv7092850" class="external text external">10.3390/v7092850</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294" class="external text external">4584294</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26389935  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26389935'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26389935" class="external text external">26389935</a>. <q>Oral nitazoxanide is an available, approved antiparasitic agent (e.g., against cryptosporidium, giardia) with established safety profiles. Recently, it has been shown (together with its active metabolite tizoxanide) to possess anti-influenza activity by blocking haemagglutinin maturation/trafficking, and acting as an interferon-inducer [97].<span>&nbsp;</span>... A large, multicenter, Phase 3 randomized-controlled trial comparing nitazoxanide, oseltamivir, and their combination in uncomplicated influenza is currently underway (NCT01610245).</q></cite><br><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294/figure/viruses-07-02850-f001/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294/figure/viruses-07-02850-f001/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584294/figure/viruses-07-02850-f001/" class="external text external">Figure 1: Molecular targets and potential antiviral treatments against influenza virus infection</a></span></li><li id="cite_note-Infectious_Diseases_2009-17"> <span id="mw-reference-text-cite_note-Infectious_Diseases_2009-17" class="mw-reference-text"><cite id="CITEREFTeranTeran-EscaleraVillarroel2009" class="citation journal cs1">Teran, C. G.; Teran-Escalera, C. N.; Villarroel, P. (2009). <a href="javascript:if(confirm('https://doi.org/10.1016/j.ijid.2008.09.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.ijid.2008.09.014'" tppabs="https://doi.org/10.1016/j.ijid.2008.09.014" class="external text external">"Nitazoxanide vs. Probiotics for the treatment of acute rotavirus diarrhea in children: A randomized, single-blind, controlled trial in Bolivian children"</a>. <i>International Journal of Infectious Diseases</i>. <b>13</b> (4): 518–523. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijid.2008.09.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijid.2008.09.014'" tppabs="https://doi.org/10.1016%2Fj.ijid.2008.09.014" class="external text external">10.1016/j.ijid.2008.09.014</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19070525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19070525'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19070525" class="external text external">19070525</a>.</cite></span></li><li id="cite_note-Infectious_Diseases_2008-18"> <span id="mw-reference-text-cite_note-Infectious_Diseases_2008-18" class="mw-reference-text"><cite id="CITEREFLateefZargarKhanNazir2008" class="citation journal cs1">Lateef, M.; Zargar, S. A.; Khan, A. R.; Nazir, M.; Shoukat, A. (2008). <a href="javascript:if(confirm('https://doi.org/10.1016/j.ijid.2007.04.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.ijid.2007.04.017'" tppabs="https://doi.org/10.1016/j.ijid.2007.04.017" class="external text external">"Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide"</a>. <i>International Journal of Infectious Diseases</i>. <b>12</b> (1): 80–82. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijid.2007.04.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijid.2007.04.017'" tppabs="https://doi.org/10.1016%2Fj.ijid.2007.04.017" class="external text external">10.1016/j.ijid.2007.04.017</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17962058  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17962058'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17962058" class="external text external">17962058</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text">World Journal of Gastroenterology 2009 April 21, Emmet B Keeffe MD, Professor, Jean-François Rossignol The Romark Institute for Medical Research, Tampa</span></li><li id="cite_note-Hepatitis_B_and_C-20"> <span id="mw-reference-text-cite_note-Hepatitis_B_and_C-20" class="mw-reference-text"><cite id="CITEREFKeeffeRossignol2009" class="citation journal cs1">Keeffe, E. B.; Rossignol, J. F. (2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670405  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670405'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670405" class="external text external">"Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides"</a>. <i>World Journal of Gastroenterology</i>. <b>15</b> (15): 1805–1808. doi:<a href="javascript:if(confirm('https://doi.org/10.3748%2Fwjg.15.1805  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3748%2Fwjg.15.1805'" tppabs="https://doi.org/10.3748%2Fwjg.15.1805" class="external text external">10.3748/wjg.15.1805</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670405  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670405'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670405" class="external text external">2670405</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19370775  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19370775'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19370775" class="external text external">19370775</a>.</cite></span></li><li id="cite_note-NikolovaGluud2014-21"> <span id="mw-reference-text-cite_note-NikolovaGluud2014-21" class="mw-reference-text"><cite id="CITEREFNikolovaGluudGrevstadJakobsen2014" class="citation journal cs1">Nikolova, Kristiana; Gluud, Christian; Grevstad, Berit; Jakobsen, Janus C (2014). "Nitazoxanide for chronic hepatitis C". <i>Cochrane Database of Systematic Reviews</i> (4): CD009182. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD009182.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD009182.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD009182.pub2" class="external text external">10.1002/14651858.CD009182.pub2</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1465-1858  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1465-1858'" tppabs="https://www.worldcat.org/issn/1465-1858" class="external text external">1465-1858</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24706397  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24706397'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24706397" class="external text external">24706397</a>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('http://www.medicalnewstoday.com/articles/79780.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicalnewstoday.com/articles/79780.php'" tppabs="http://www.medicalnewstoday.com/articles/79780.php" class="external text external">"Romark Initiates Clinical Trial Of Alinia For Chronic Hepatitis C In The United States"</a> (Press release). Medical News Today. August 16, 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-10-11</span></span>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFFranciscus2007" class="citation web cs1">Franciscus, Alan (October 2, 2007). <a href="javascript:if(confirm('https://web.archive.org/web/20030906003433/http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20030906003433/http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html'" tppabs="https://web.archive.org/web/20030906003433/http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html" class="external text external">"Hepatitis C Treatments in Current Clinical Development"</a>. HCV Advocate. Archived from <a href="javascript:if(confirm('http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html'" tppabs="http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html" class="external text external">the original</a> on September 6, 2003<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-10-11</span></span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFRossignolAbu-ZekryHusseinSantoro2006" class="citation journal cs1">Rossignol, Jean-François; Abu-Zekry, Mona; Hussein, Abeer; Santoro, M Gabriella (2006). "Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial". <i>The Lancet</i>. <b>368</b> (9530): 124–9. CiteSeerX<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.458.1597  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.458.1597'" tppabs="https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.458.1597" class="external text external">10.1.1.458.1597</a></span>. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2806%2968852-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2806%2968852-1'" tppabs="https://doi.org/10.1016%2FS0140-6736%2806%2968852-1" class="external text external">10.1016/S0140-6736(06)68852-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16829296  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16829296'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16829296" class="external text external">16829296</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFDanSobel2007" class="citation journal cs1">Dan, M.; Sobel, J. D. (2007). "Failure of Nitazoxanide to Cure Trichomoniasis in Three Women". <i>Sexually Transmitted Diseases</i>. <b>34</b> (10): 813–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FNMD.0b013e31802f5d9a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FNMD.0b013e31802f5d9a'" tppabs="https://doi.org/10.1097%2FNMD.0b013e31802f5d9a" class="external text external">10.1097/NMD.0b013e31802f5d9a</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17551415  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17551415'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17551415" class="external text external">17551415</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nlm.nih.gov/medlineplus/druginfo/meds/a603017.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nlm.nih.gov/medlineplus/druginfo/meds/a603017.html'" tppabs="https://www.nlm.nih.gov/medlineplus/druginfo/meds/a603017.html" class="external text external">"Nitazoxanide"</a>. <i>MedlinePlus</i><span class="reference-accessdate">. Retrieved <span class="nowrap">9 April</span> 2014</span>.</cite></span></li><li id="cite_note-pmid28748751-27"> <span id="mw-reference-text-cite_note-pmid28748751-27" class="mw-reference-text"><cite id="CITEREFShakyaBhatGhosh2018" class="citation journal cs1">Shakya, A; Bhat, HR; Ghosh, SK (2018). "Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent". <i>Current Drug Discovery Technologies</i>. <b>15</b> (3): 201–213. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F1570163814666170727130003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F1570163814666170727130003'" tppabs="https://doi.org/10.2174%2F1570163814666170727130003" class="external text external">10.2174/1570163814666170727130003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28748751  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28748751'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28748751" class="external text external">28748751</a>.</cite></span></li><li id="cite_note-Rossignol2009-28"> <span id="mw-reference-text-cite_note-Rossignol2009-28" class="mw-reference-text"><cite id="CITEREFRossignolLa_FraziaChiappaCiucci2009" class="citation journal cs1">Rossignol, J. F.; La Frazia, S.; Chiappa, L.; Ciucci, A.; Santoro, M. G. (2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785610  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785610'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785610" class="external text external">"Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level"</a>. <i>Journal of Biological Chemistry</i>. <b>284</b> (43): 29798–29808. doi:<a href="javascript:if(confirm('https://doi.org/10.1074%2Fjbc.M109.029470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074%2Fjbc.M109.029470'" tppabs="https://doi.org/10.1074%2Fjbc.M109.029470" class="external text external">10.1074/jbc.M109.029470</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785610  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785610'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785610" class="external text external">2785610</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19638339  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19638339'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19638339" class="external text external">19638339</a>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFWhite_Jr2003" class="citation journal cs1">White Jr, AC (2003). <a href="javascript:if(confirm('https://doi.org/10.4269/ajtmh.2003.68.382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4269/ajtmh.2003.68.382'" tppabs="https://doi.org/10.4269/ajtmh.2003.68.382" class="external text external">"Nitazoxanide: An important advance in anti-parasitic therapy"</a>. <i>Am. J. Trop. Med. Hyg</i>. <b>68</b> (4): 382–383. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.4269%2Fajtmh.2003.68.382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4269%2Fajtmh.2003.68.382'" tppabs="https://doi.org/10.4269%2Fajtmh.2003.68.382" class="external text external">10.4269/ajtmh.2003.68.382</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12875283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12875283'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12875283" class="external text external">12875283</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite class="citation journal cs1">Lateef, M.; Zargar, S. A.; Khan, A. R.; Nazir, M.; Shoukat, A. (2008). <a href="javascript:if(confirm('https://doi.org/10.1016/j.ijid.2007.04.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.ijid.2007.04.017'" tppabs="https://doi.org/10.1016/j.ijid.2007.04.017" class="external text external">"Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide"</a>. <i>International Journal of Infectious Diseases</i>. <b>12</b> (1): 80–2. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijid.2007.04.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijid.2007.04.017'" tppabs="https://doi.org/10.1016%2Fj.ijid.2007.04.017" class="external text external">10.1016/j.ijid.2007.04.017</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17962058  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17962058'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17962058" class="external text external">17962058</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite id="CITEREFLiuZhouLiGarner2020" class="citation journal cs1">Liu, Cynthia; Zhou, Qiongqiong; Li, Yingzhu; Garner, Linda V.; Watkins, Steve P.; Carter, Linda J.; Smoot, Jeffrey; Gregg, Anne C.; Daniels, Angela D.; Jervey, Susan; Albaiu, Dana (2020). <a href="javascript:if(confirm('https://doi.org/10.1021/acscentsci.0c00272  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021/acscentsci.0c00272'" tppabs="https://doi.org/10.1021/acscentsci.0c00272" class="external text external">"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases"</a>. <i>ACS Central Science</i>. <b>6</b>: 315–331. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1021%2Facscentsci.0c00272  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Facscentsci.0c00272'" tppabs="https://doi.org/10.1021%2Facscentsci.0c00272" class="external text external">10.1021/acscentsci.0c00272</a></span>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation journal cs1">"Abdul Kadhim AH1, Hadi NR1, Abdulhussein M2, Zamil ST2 and Zamil ST2(2020). Preprocessing of the Candidate Antiviral Drugs against COVID-19 in Models of SARS cov2 Targets. LPMA. vol.106".</cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li></ol></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nlm.nih.gov/medlineplus/druginfo/meds/a603017.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nlm.nih.gov/medlineplus/druginfo/meds/a603017.html'" tppabs="https://www.nlm.nih.gov/medlineplus/druginfo/meds/a603017.html" class="external text external">"Nitazoxanide"</a>. <i>MedlinePlus Drug Information</i>. U.S. National Library of Medicine. 28 July 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-08-19</span></span>.</cite></li>
<li><cite class="citation journal cs1"><a href="javascript:if(confirm('https://semanticscholar.org/paper/44b9bd592068f52882ac3f50acf762e2c4c66f02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/44b9bd592068f52882ac3f50acf762e2c4c66f02'" tppabs="https://semanticscholar.org/paper/44b9bd592068f52882ac3f50acf762e2c4c66f02" class="external text external">"Parasitic infections"</a>. <i>Am J Transplant</i>. <b>4</b> (Suppl 10): 142–55. 2004. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1600-6135.2004.00677.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1600-6135.2004.00677.x'" tppabs="https://doi.org/10.1111%2Fj.1600-6135.2004.00677.x" class="external text external">10.1111/j.1600-6135.2004.00677.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15504227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15504227'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15504227" class="external text external">15504227</a>.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Antiparasitics_–_antiprotozoal_agents_–_Chromalveolata_antiparasitics_(P01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antiparasitics_–_antiprotozoal_agents_–_Chromalveolata_antiparasitics_(P01)" style="font-size:114%;margin:0 4em">Antiparasitics – antiprotozoal agents – Chromalveolata antiparasitics (P01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Alveo-<br>late</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Apicom-<br>plexa</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Conoidasida/<br>(Coccidiostats)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Cryptosporidiosis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><span class="new">thiazolides</span></i> (<a href="Nitazoxanide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitazoxanide" title="Nitazoxanide">nitazoxanide</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Isosporiasis</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Trimethoprim/sulfamethoxazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Trimethoprim/sulfamethoxazole" title="Trimethoprim/sulfamethoxazole">trimethoprim/sulfamethoxazole</a><sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Toxoplasmosis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Pyrimethamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimethamine" title="Pyrimethamine">pyrimethamine</a></li>
<li><a href="Sulfadiazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfadiazine" title="Sulfadiazine">sulfadiazine</a></li>
<li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">clindamycin</a></li>
<li><a href="Atovaquone.htm" tppabs="https://ptable.com/wiki/compounds/A/Atovaquone" title="Atovaquone">atovaquone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Aconoidasida</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Malaria</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Individual <br>agents</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Hemozoin<br>inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Aminoquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoquinoline" title="Aminoquinoline">Aminoquinolines</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>(4-): <a href="Amodiaquine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amodiaquine" title="Amodiaquine">amodiaquine</a><sup>#</sup></li>
<li><a href="Chloroquine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chloroquine" title="Chloroquine">chloroquine</a><sup>#</sup></li>
<li><a href="Hydroxychloroquine.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroxychloroquine" title="Hydroxychloroquine">hydroxychloroquine</a><sup>#</sup></li></ul>

<ul><li><a href="8-Aminoquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Aminoquinoline" title="8-Aminoquinoline">(8-)</a>: <a href="Primaquine.htm" tppabs="https://ptable.com/wiki/compounds/A/Primaquine" title="Primaquine">primaquine</a><sup>#</sup></li>
<li>pamaquine<sup>‡</sup></li>
<li>tafenoquine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">4-Methanolquinolines</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mefloquine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mefloquine" title="Mefloquine">mefloquine</a><sup>#</sup></li>
<li><a href="Quinine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinine" title="Quinine">quinine</a><sup>#</sup></li>
<li><a href="Quinidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinidine" title="Quinidine">quinidine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lumefantrine
<ul><li>+ artemether<sup>#</sup></li></ul></li></ul>

<ul><li><a href="Halofantrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Halofantrine" title="Halofantrine">halofantrine</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antifolates</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">DHFR inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Pyrimethamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimethamine" title="Pyrimethamine">pyrimethamine</a></li></ul>

<ul><li><i>biguanides</i>
<ul><li>chlorproguanil</li>
<li><a href="Proguanil.htm" tppabs="https://ptable.com/wiki/compounds/A/Proguanil" title="Proguanil">proguanil</a><sup>#</sup></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Sulfonamides</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sulfadoxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfadoxine" title="Sulfadoxine">sulfadoxine</a></li>
<li><a href="Sulfalene.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfalene" title="Sulfalene">sulfalene</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Co-formulation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>sulfadoxine/pyrimethamine (SP)<sup>#</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Sesquiterpene<br>lactones</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Artemether.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemether" title="Artemether">artemether</a><sup>#</sup></li>
<li><a href="Artemisinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemisinin" title="Artemisinin">artemisinin</a></li>
<li>artemotil</li>
<li>artesunate<sup>#</sup></li>
<li>dihydroartemisinin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Atovaquone.htm" tppabs="https://ptable.com/wiki/compounds/A/Atovaquone" title="Atovaquone">atovaquone</a> (+ proguanil)</li>
<li><a href="Tetracycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetracycline" title="Tetracycline">tetracycline</a></li>
<li><a href="Doxycycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxycycline" title="Doxycycline">doxycycline</a><sup>#</sup></li>
<li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">clindamycin</a></li>
<li>mepacrine</li>
<li>pyronaridine</li>
<li>piperaquine</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combi-<br>nations</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Fixed-dose_(co-formulated)_ACTs" scope="row" class="navbox-group" style="width:1%">Fixed-dose (co-formulated)  <a href="Artemisinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemisinin" title="Artemisinin">ACTs</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>artemether/lumefantrine<sup>#</sup></li>
<li>arterolane/piperaquine</li>
<li>artesunate/amodiaquine (ASAQ)</li>
<li>artesunate/mefloquine (ASMQ)</li>
<li>artesunate/pyronaridine</li>
<li>piperaquine/dihydroartemisinin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other combinations<br>(not co-formulated)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>artesunate/mefloquine</li>
<li>artesunate/SP</li>
<li>quinine/clindamycin</li>
<li>quinine/doxycycline</li>
<li>quinine/tetracycline</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Babesiosis</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">clindamycin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cilio-<br>phora</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Balantidiasis: <a href="Tetracycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetracycline" title="Tetracycline">tetracycline</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hetero-<br>kont</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Blastocystosis: <a href="Metronidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metronidazole" title="Metronidazole">metronidazole</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Antiparasitics_–_antiprotozoal_agents_–_Excavata_antiparasitics_(P01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antiparasitics_–_antiprotozoal_agents_–_Excavata_antiparasitics_(P01)" style="font-size:114%;margin:0 4em">Antiparasitics<span>&nbsp;</span>– antiprotozoal agents<span>&nbsp;</span>– Excavata antiparasitics (P01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Discicristata</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Trypanosomiasis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">African trypanosomiasis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Ornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ornithine" title="Ornithine">ornithine</a> (<a href="Eflornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Eflornithine" title="Eflornithine">Eflornithine</a><sup>#</sup>)</li>
<li>arsenical (Melarsoprol<sup>#</sup>)</li>
<li><a href="Benzamidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzamidine" title="Benzamidine">benzamidine</a> (<a href="Pentamidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pentamidine" title="Pentamidine">Pentamidine</a><sup>#</sup>)</li>
<li>naphthalenesulfonate (<a href="Suramin.htm" tppabs="https://ptable.com/wiki/compounds/A/Suramin" title="Suramin">Suramin</a><sup>#</sup>)<br></li>
<li>nitroimidazole (Fexinidazole<sup>†</sup>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chagas disease</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>nitroimidazole (Benznidazole<sup>#</sup>)</li>
<li>nitrofuran (Nifurtimox<sup>#</sup>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leishmaniasis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>macrolide (<a href="Amphotericin_B.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphotericin_B" title="Amphotericin B">Amphotericin B</a><sup>#</sup>)</li></ul>

<p>Pentavalent antimonials (Meglumine antimoniate<sup>#</sup>, <a href="Sodium_stibogluconate.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium_stibogluconate" title="Sodium stibogluconate">Sodium stibogluconate</a>)</p>

<ul><li><a href="Benzamidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzamidine" title="Benzamidine">benzamidine</a> (<a href="Pentamidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pentamidine" title="Pentamidine">Pentamidine</a><sup>#</sup>)</li>
<li>phosphorylcholine (<a href="Miltefosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Miltefosine" title="Miltefosine">Miltefosine</a>)</li>
<li><a href="Neomycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Neomycin" title="Neomycin">neomycin</a> (<a href="Paromomycin_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Paromomycin_sulfate" title="Paromomycin sulfate" class="mw-redirect">Paromomycin</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">PAM</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>macrolide (<a href="Amphotericin_B.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphotericin_B" title="Amphotericin B">Amphotericin B</a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Trichozoa</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Giardiasis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>nitroimidazole (<a href="Metronidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metronidazole" title="Metronidazole">Metronidazole</a><sup>#</sup>, <a href="Tinidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Tinidazole" title="Tinidazole">Tinidazole</a>)</li>
<li><a href="Benzimidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzimidazole" title="Benzimidazole">benzimidazole</a> (<a href="Albendazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Albendazole" title="Albendazole">Albendazole</a>)</li></ul>

<ul><li><span class="new">thiazolide</span> (<a href="Nitazoxanide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitazoxanide" title="Nitazoxanide">Nitazoxanide</a>)</li>
<li>nitrofuran (<a href="Furazolidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazolidone" title="Furazolidone">Furazolidone</a>)</li></ul>

<ul><li><a href="9-Aminoacridine.htm" tppabs="https://ptable.com/wiki/compounds/A/9-Aminoacridine" title="9-Aminoacridine">aminoacridine</a> (<a href="Quinacrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinacrine" title="Quinacrine" class="mw-redirect">Quinacrine</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Trichomoniasis</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>nitroimidazole (Carnidazole, <a href="Metronidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metronidazole" title="Metronidazole">Metronidazole</a><sup>#</sup>, <a href="Tinidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Tinidazole" title="Tinidazole">Tinidazole</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Dientamoebiasis</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>nitroimidazole (<a href="Metronidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metronidazole" title="Metronidazole">Metronidazole</a></li>
<li>Secnidazole)<br></li></ul>

<ul><li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxyquinoline" title="Oxyquinoline" class="mw-redirect">oxyquinoline</a> (<a href="Diiodohydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Diiodohydroxyquinoline" title="Diiodohydroxyquinoline">Iodoquinol</a>)</li>
<li><a href="Tetracycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetracycline" title="Tetracycline">tetracycline</a> (<a href="Doxycycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxycycline" title="Doxycycline">Doxycycline</a>)</li>
<li><a href="Neomycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Neomycin" title="Neomycin">neomycin </a> (Paromomycin)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>





<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-07-10" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Nitazoxanide&oldid=966989754  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Nitazoxanide&oldid=966989754'" tppabs="https://en.wikipedia.org/wiki/?title=Nitazoxanide&oldid=966989754">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>